Aubagio (teriflunomide) is not available as a generic product. Although one of the patents for the medicine has expired, there is an additional patent that does not expire until October 2014. This is the earliest predicted date that a generic Aubagio product might become available, unless lawsuits, new patents, or certain other circumstances come up.
Aubagio® (teriflunomide) is a prescription medication approved for the treatment of multiple sclerosis (MS). It belongs to a group of medicines known as immunomodulators, or immune-modulating medicines.
Aubagio is made by Genzyme Corporation. It is under the protection of patents that prevent any generic Aubagio from being manufactured in the United States.
The first patent for Aubagio expired in October 2012. However, Aubagio is protected by an additional patent that does not expire until October 2014. This is likely the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Aubagio uses. Once the patent expires, there may be several companies that manufacture a generic version of the drug.
No -- teriflunomide is the active ingredient in Aubagio, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer would make the product.